Save

ImmusanT discontinues phase 2 trial of celiac disease vaccine

Perspective from Peter H.R. Green, MD, MD ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on . Please provide your email address to receive an email when new articles are posted on Subscribe ADDED TO EMAIL ALERTS You've successfully added to your alerts. You will receive an email when new content is published.



Click Here to Manage Email Alerts You've successfully added to your alerts. You will receive an email when new content is published.



Click Here to Manage Email Alerts



Back to Healio We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.



Back to Healio

ImmusanT announced that it will discontinue its phase 2 global study of Nexvax2, a peptide-based immunomodulatory vaccine intended to treat celiac disease, according to a company press release.

Although Nexvax2 has been found to be safe and well-tolerated, an interim analysis demonstrated that the vaccine did not provide statistically meaningful protection from gluten exposure for patients with celiac disease compared with placebo.

When reached for comment, ImmusanT said that it “is continuing to compile and analyze information regarding the outcome of this study and will be providing an update accordingly.”